LEADER 04511nam 22006015 450 001 9910492153003321 005 20251113173856.0 010 $a981-16-0267-0 024 7 $a10.1007/978-981-16-0267-2 035 $a(CKB)4100000011982479 035 $a(MiAaPQ)EBC6678852 035 $a(Au-PeEL)EBL6678852 035 $a(PPN)258059397 035 $a(OCoLC)1260292064 035 $a(DE-He213)978-981-16-0267-2 035 $a(EXLCZ)994100000011982479 100 $a20210713d2021 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntiviral Drug Discovery and Development /$fedited by Xinyong Liu, Peng Zhan, Luis Menéndez-Arias, Vasanthanathan Poongavanam 205 $a1st ed. 2021. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2021. 215 $a1 online resource (364 pages) 225 1 $aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v1322 311 08$a981-16-0266-2 320 $aIncludes bibliographical references. 327 $a1 Antiviral Drugs Against Herpesviruses -- 2 An Update on Antiretroviral Therapy -- 3 Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and their Inhibition -- 4 LEDGINs, Inhibitors of the Interaction between HIV-1 Integrase and LEDGF/p75, are Potent Antivirals with a Potential to Cure HIV Infection -- 5 Moving Fast Towards Hepatitis B Virus Elimination -- 6 Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection -- 7 Phytoconstituents as Lead Compounds for Anti-dengue Drug Discovery -- 8 Anti-influenza Drug Discovery and Development: Targeting the Virus and its Host by all -- 9 Search, Identification and Design of Effective Antiviral Drugs against Pandemic Human Coronaviruses -- 10 Peptide Based Antiviral Drugs -- 11 Covalent Antiviral Agents -- 12 Safe-in-Man Broad Spectrum Antiviral Agents -- 13 Exploiting Ubiquitin ligases for Induced Target Degradation as an Antiviral Strategy. . 330 $aThis book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development. Special attention is paid to viral infections with a high impact on the world population or highly relevant from the public health perspective (HIV, hepatitis C, influenza virus, etc.). In these chapters, limitations associated with adverse effects and emergence of drug resistance are discussed in detail. In addition to classical antiviral strategies, chapters will be dedicated to discuss the non-classical drug development strategies to block viral infection, for instance, allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting protein?protein interactions. Finally, current prospects for producing broad-spectrum antiviral inhibitors will be also addressed. The book is distinctive in providing the most recent update in the rapidly evolving field of antiviral therapeutics. Authoritative reviews are written by international scientists well known for their contributions in their topics of research, which makes this book suitable for researchers not only within the antiviral research community but also attractive to a broad audience in the drug discovery field. This book covers molecular structures and biochemical mechanisms mediating the antiviral effects, while discussing various ligand design strategies, which include traditional medicinal chemistry, computational chemistry, and chemical biology approaches. The book provides a comprehensive review of antiviral drug discovery and development approaches, particularly focusing on current innovations and future trends. 410 0$aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v1322 606 $aPharmacology 606 $aPharmacy 606 $aBiotechnology 606 $aPharmacology 606 $aPharmacy 606 $aBiotechnology 615 0$aPharmacology. 615 0$aPharmacy. 615 0$aBiotechnology. 615 14$aPharmacology. 615 24$aPharmacy. 615 24$aBiotechnology. 676 $a615.7924 702 $aLiu$b Xinyong 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910492153003321 996 $aAntiviral Drug Discovery and Development$92072136 997 $aUNINA